August 09, 2021
Article
Drugs, personnel, and laboratory costs comprised 50%, 38%, and 12% of program costs.
July 23, 2021
Video
A discussion as to why people with unstable housing living with HIV may not prefer telehealth versus consistent in-person care.
The risk of COVID-19 severity in people living with HIV may be less than previously anticipated.
Phase 3 trials for islatravir are underway. What are investigators considering with the Merck investigative drug?
July 22, 2021
Due to limited familiarity with providing antiretroviral medication, many participants were hesitant to initiate PrEP.
Investigators wanted to study usage of F/TAF vs F/TDF in clinical practice and HIV seroconversion.
July 21, 2021
Adherence for daily dosing decreased and event-driven PrEP usage increased in a Chinese study.
Impaired resilience was found to be associated with loneliness.
Virtual support services were crucial for providing continued care and education.
In a pilot project, customers were surveyed about HIV risk behaviors to gain further insights and assessed for potential PrEP utilization.
What Content Do You Want to See From Contagion?
Clinical Considerations in Conducting Antifungal Susceptibility Testing
Investigational Vaccine Meets RSV Inoculation Challenge
HIV Testing and Diagnoses Drop During COVID-19 Pandemic
